Vertex Pharmaceuticals’ positive results from CASGEVY trial highlighted at ASH

Vertex Pharmaceuticals “announced two oral presentations at the American Society of Hematology, ASH, Annual Meeting and Exposition from the global pivotal trials of CASGEVY. Data from 96 patients, 44 sickle cell disease, 52 transfusion-dependent beta thalassemia treated with CASGEVY in pivotal studies, with the longest follow-up of more than four years, continue to reinforce the consistent and durable response to treatment. In addition, new data illustrating improvements in patient-reported outcomes after treatment with CASGEVY were featured in poster presentations at ASH.” Chief Medical Officer Carmen Bozic states: “We are excited to share this comprehensive data set with the broader community today, just days after FDA approval of CASGEVY for the treatment of severe sickle cell disease. These data demonstrate the consistent and durable efficacy of CASGEVY in eliminating severe vaso-occlusive crises in patients with SCD and conferring transfusion independence in patients with TDT.”